Decreased salivary lactoferrin levels are specific to Alzheimer's disease

Background: Evidences of infectious pathogens in Alzheimer's disease (AD) brains may suggest a deteriorated innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf) levels, one of the major antimicrobial proteins, in AD patients. Methods: To asses...

Descripción completa

Detalles Bibliográficos
Autores: González Sánchez, Marta, Bartolomé, Fernando, Antequera, Desirée, Puertas Martín, Verónica, González, Pilar, Gómez Grande, Adolfo, Llamas Velasco, Sara, Herrero San Martín, Alejandro, Pérez Martínez, David, Villarejo Galende, Alberto, Atienza, Mercedes, Palomar Bonete, Miriam, Cantero, José Luis, Perry, George, Orive Arroyo, Gorka, Ibáñez, Borja, Bueno, Héctor, Fuster, Valentín, Carro, Eva
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/47307
Acceso en línea:http://hdl.handle.net/10810/47307
Access Level:acceso abierto
Palabra clave:Alzheimer's disease
lactoferrin
saliva
PET imaging
biomarkers
frontotemporal dementia
mild cognitive impairment
herpes-simplex infection
association workgroups
diagnostic guidelines
national institute
amyloid-beta
apolipoprotein-e
potential role
brain
recommendations
Descripción
Sumario:Background: Evidences of infectious pathogens in Alzheimer's disease (AD) brains may suggest a deteriorated innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf) levels, one of the major antimicrobial proteins, in AD patients. Methods: To assess the clinical utility of salivary Lf for AD diagnosis, we examine the relationship between salivary Lf and cerebral amyloid-beta (A beta) load using amyloid-Positron-Emission Tomography (PET) neuroimaging, in two different cross-sectional cohorts including patients with different neurodegenerative disorders. Findings: The diagnostic performance of salivary Lf in the cohort 1 had an area under the curve [AUC] of 0.95 (0.911-0.992) for the differentiation of the prodromal AD/AD group positive for amyloid-PET (PET+) versus healthy group, and 0.97 (0.924-1) versus the frontotemporal dementia (FTD) group. In the cohort 2, salivary Lf had also an excellent diagnostic performance in the health control group versus prodromal AD comparison: AUC 0.93 (0.876-0.989). Salivary Lf detected prodromal AD and AD dementia distinguishing them from FTD with over 87% sensitivity and 91% specificity. Interpretation: Salivary Lf seems to have a very good diagnostic performance to detect AD. Our findings support the possible utility of salivary Lf as a new non-invasive and cost-effective AD biomarker.

Similares en LA Referencia